MAP Pharmaceuticals recent weakness a buying opportunity, says Wedbush
Wedbush believes MAP's latest patent strengthens Levadex's IP protection and recommends using the recent weakness in the stock as a buying opportunity. :theflyonthewall.com
News For MAPP From The Last 14 Days
Check below for free stories on MAPP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
